4.8 Article

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 123, Issue 4, Pages 1542-1555

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI66517

Keywords

-

Funding

  1. Noxxon
  2. Bristol-Myers Squibb
  3. GlaxoSmithKline
  4. NIH [R01CA154648, R01CA133799, R01CA125690]
  5. Accademia Nazionale dei Lincei (Rome, Italy)

Ask authors/readers for more resources

BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but little is known about the putative mechanisms by which the BM microenvironment plays an oncogenic role in this disease. Cell-cell communication is mediated by exosomes. In this study, we showed that MM BM-MSCs release exosomes that are transferred to MM cells, thereby resulting in modulation of tumor growth in vivo. Exosomal microRNA (miR) content differed between MM and normal BM-MSCs, with a lower content of the tumor suppressor miR-15a. In addition, MM BM-MSC-derived exosomes had higher levels of oncogenic proteins, cytokines, and adhesion molecules compared with exosomes from the cells of origin. Importantly, whereas MM BM-MSC-derived exosomes promoted MM tumor growth, normal BM-MSC exosomes inhibited the growth of MM cells. In summary, these in vitro and in vivo studies demonstrated that exosome transfer from BM-MSCs to clonal plasma cells represents a previously undescribed and unique mechanism that highlights the contribution of BM-MSCs to MM disease progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available